Author

Marin JJG

University of Salamanca, Dept. Physiology and Pharmacology, HEVEPHARM, IBSAL, CIBERehd, Salamanca - Cited by 15,639 - Hepatology - Pathophysiology - Pharmacology - Chemoresistance

Biography

Dr. Marin JJG is an Associate professor in the Experimental Hepatology and Drug Targeting (HEVEFARM), University of Salamanca, IBSAL, Salamanca, Spain. His study interests major on Physiology and Pharmacology. In recent years, he has studied several on Hepatology, Pathophysiology, Pharmacology. Currently , Dr. Marin is the author/editors/reviewer in several international journals. He published 63 articles in many journals and the articles are informative and got good citations.
Title
Cited by
Year
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
L Izquierdo-Sanchez, A Lamarca, A La Casta, S Buettner, K Utpatel, ...Journal of hepatology 76 (5), 1109-1121, 2022202
73
2022
STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway
LC de la Rosa, C Garcia-Ruiz, C Vallejo, A Baulies, S Nuñez, MJ Monte, ...Journal of hepatology 74 (6), 1429-1441, 2021202
26
2021
Dual targeting of G9a and DNA methyltransferase‐1 for the treatment of experimental cholangiocarcinoma
L Colyn, M Bárcena‐Varela, G Álvarez‐Sola, MU Latasa, I Uriarte, ...Hepatology 73 (6), 2380-2396, 2021202
25
2021
Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis
M Serrano-Maciá, J Simón, MJ González-Rellan, M Azkargorta, ...Molecular metabolism 53, 101275, 2021202
16
2021
Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs
JJG Marin, RIR MaciasExpert Opinion on Investigational Drugs 30 (7), 675-679, 2021202
12
2021
Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics
RIR Macias, MJ Monte, MA Serrano, JM González-Santiago, ...Aging (Albany NY) 13 (19), 23416, 2021202
12
2021
Impact of alternative splicing on mechanisms of resistance to anticancer drugs
M Reviejo, M Soto, E Lozano, M Asensio, O Martinez-Augustin, ...Biochemical Pharmacology 193, 114810, 2021202
12
2021
Modulation of intestinal barrier function by glucocorticoids: Lessons from preclinical models
M Tena-Garitaonaindia, M Arredondo-Amador, C Mascaraque, M Asensio, ...Pharmacological Research 177, 106056, 2022202
12
2022
Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity
P Fernández-Tussy, R Rodríguez-Agudo, D Fernández-Ramos, ...Cell death & disease 12 (6), 555, 2021202
11
2021
Novel pharmacological options in the treatment of cholangiocarcinoma: mechanisms of resistance
JJG Marin, P Sanchon-Sanchez, C Cives-Losada, S Del Carmen, ...Cancers 13 (), 2358, 2021202
10
2021
TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation
I Labiano, A Agirre-Lizaso, P Olaizola, A Echebarria, M Huici-Izagirre, ...Journal of Hepatology 77 (4), 991-04, 2022202
10
2022
Gene supplementation of CYP27A1 in the liver restores bile acid metabolism in a mouse model of cerebrotendinous xanthomatosis
S Lumbreras, A Ricobaraza, L Baila-Rueda, M Gonzalez-Aparicio, ...Molecular Therapy-Methods & Clinical Development 22, 210-221, 2021202
9
2021
Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury
P Iruzubieta, N Goikoetxea-Usandizaga, L Barbier-Torres, ...JHEP Reports 3 (3), 100276, 2021202
9
2021
Expression of chemoresistance-associated abc proteins in hepatobiliary, pancreatic and gastrointestinal cancers
JJG Marin, MJ Monte, RIR Macias, MR Romero, E Herraez, M Asensio, ...Cancers 14 (14), 3524, 2022202
8
2022
Mechanisms of pharmacoresistance in hepatocellular carcinoma: New drugs but old problems
JJG Marin, MR Romero, E Herraez, M Asensio, S Ortiz-Rivero, ...Seminars in Liver Disease 42 (01), 07-103, 2021202
8
2021
Association of FOXO3 expression with tumor pathogenesis, prognosis and clinicopathological features in hepatocellular carcinoma: a systematic review with meta-analysis
F Fondevila, P Fernández-Palanca, C Méndez-Blanco, T Payo-Serafín, ...Cancers 13 (21), 5349, 2021202
7
2021
Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia
A Albasanz-Puig, X Durà-Miralles, J Laporte-Amargós, A Mussetti, ...Microorganisms 10 (4), 733, 2022202
6
2022
Impact of alternative splicing variants on liver cancer biology
JJG Marin, M Reviejo, M Soto, E Lozano, M Asensio, S Ortiz-Rivero, ...Cancers 14 (1), 18, 2021202
6
2021
Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models
P Olaizola, PY Lee-Law, MG Fernandez-Barrena, L Alvarez, M Cadamuro, ...Journal of Hepatology 77 (1), 177-190, 2022202
5
2022
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
L Colyn, G Alvarez-Sola, MU Latasa, I Uriarte, JM Herranz, M Arechederra, ...Journal of Experimental & Clinical Cancer Research 1 (1), 183, 2022202
4
2022

Referred From: https://scholar.google.com/citations?hl=en&user=L5brTHIAAAAJ

Cited by
Citations 15639
h-index 62
i10-index 234
Recommended Journals
Open Access Journals